Below are the most recent publications written about "Antineoplastic Agents" by people in Profiles.
-
Axeen S, Chen AJ, Lakdawalla DN, Masia N, Niyazov A, Arondekar B, Freedland SJ. Do trial benefits predict real-world gains in metastatic castration resistant prostate cancer. JNCI Cancer Spectr. 2025 Mar 03; 9(2).
-
Schilder RJ, Rasco D, Sharma MR. An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors. Neoplasia. 2025 03; 61:101133.
-
Ye Q, Shvartsbart A, Li Z, Gan P, Policarpo RL, Qi C, Roach JJ, Zhu W, McCammant MS, Hu B, Li G, Yin H, Carlsen P, Hoang G, Zhao L, Susick R, Zhang F, Lai CT, Allali Hassani A, Epling LB, Gallion A, Kurzeja-Lipinski K, Gallagher K, Roman V, Farren MR, Kong W, Deller MC, Zhang G, Covington M, Diamond S, Kim S, Yao W, Sokolsky A, Wang X. Discovery of INCB159020, an Orally Bioavailable KRAS G12D Inhibitor. J Med Chem. 2025 Jan 23; 68(2):1924-1939.
-
Shields CL, Medina R, Evans H, Valdes-Perez N, Acar AB, Bansal R, Lally SE, Shields JA. HIGH-DOSE INTRAVITREAL TOPOTECAN FOR RECURRENT RETINOBLASTOMA, SUBRETINAL SEEDS, AND VITREOUS SEEDS. Retina. 2025 01 01; 45(1):1-6.
-
Alshahrani AA, Kontopantelis E, Morgan C, Ravindrarajah R, Martin GP, Mamas MA. Cardiovascular diseases in patients with cancer: A comprehensive review of epidemiological trends, cardiac complications, and prognostic implications. Chin Med J (Engl). 2025 Jan 20; 138(2):143-154.
-
Lingappa AF, Akintunde O, Samueli E, Ewald C, Michon M, Ziari N, Lu M, Yu SF, Froehlich M, Le PU, Fernandez Y, Mallesh S, Lin J, Kitaygorodskyy A, Solas D, Reed JC, Lingappa JR, M?ller-Schiffmann A, Korth C, Prasad D, Nalca A, Aston E, Fabbri B, Anand SK, Campi TW, Petrouski E, Dey D, Andrews DW, Rubenstein JL, Lingappa VR. Small molecule protein assembly modulators with pan-cancer therapeutic efficacy. Open Biol. 2024 12; 14(12):240210.
-
Leventhal J, Madiedo ASA, Andriessen A, Choi JN, Ho A, McLellan B, Mitchell E, Lacouture M. INDIVIDUAL ARTICLE: USCOM IV Algorithm for the Prevention and Management of Targeted Therapy-Related Cutaneous Adverse Events. J Drugs Dermatol. 2024 Dec 01; 23(12):436613s3-436613s14.
-
Udumula MP, Rashid F, Singh H, Pardee T, Luther S, Bhardwaj T, Anjaly K, Piloni S, Hijaz M, Gogoi R, Philip PA, Munkarah AR, Giri S, Rattan R. Targeting mitochondrial metabolism with CPI-613 in chemoresistant ovarian tumors. J Ovarian Res. 2024 Nov 14; 17(1):226.
-
Mondal A, Das B, Karmakar S, Pani S, Khan S, Gupta P, Das Sarma J. Modulatory Role of Pantropic Cell Signaling Pathways in the Antimigratory and Antiproliferative Action of Triazole Chelated Iridium(III) Complexes in Cervical Cancer Cells. J Med Chem. 2024 Nov 28; 67(22):20559-20570.
-
Hunter AM, Patnaik MM, Itzykson R, Mesa R, Karanes C, Li Y, de Claro RA, Norsworthy KJ, Theoret M, Pulte E, Padron E. Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm. Blood. 2024 Nov 07; 144(19):1987-1992.